echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > NEJM: Efficacy of intravenous alteplase before endovascular treatment in stroke patients

    NEJM: Efficacy of intravenous alteplase before endovascular treatment in stroke patients

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The value of intravenous alteplase before endovascular therapy (EVT) in patients with acute ischemic stroke has not been extensively studied, especially in non-Asian populations .

    Stroke blood vessel

    Recently, a research article was published in the top medical journal NEJM.


    Researchers conducted an open-label, multi-center, randomized trial in Europe, and included direct consultations in a company that can provide EVT and is eligible for intravenous alteplase treatment and Stroke patient at EVT Hospital


    The primary endpoint of the study was the functional outcome of the modified Rankin scale (range 0 [no disability] to 6 [death]) at 90 days
    .


    The researchers evaluated the superiority of EVT alone over alteplase combined with EVT, as well as the non-inferiority of the odds ratio of the two test groups and the lower limit of the 95% confidence interval of 0.


    The study analyzed 539 patients
    .


    The median score of the modified Rankin Scale at 90 days was 3 (interquartile range 2 to 5), with EVT alone, and 2 (interquartile range 2 to 5) in the alteplase combined with EVT group


    Thus, in this randomized trial involving European patients, EVT alone was neither superior nor inferior to EVT after intravenous alteplase treatment in terms of the 90-day post-stroke disability outcome
    .


    The incidence of symptomatic cerebral hemorrhage was similar in the two groups


    In this randomized trial involving European patients, EVT alone was neither superior nor inferior to EVT after intravenous alteplase treatment in terms of the 90-day post-stroke disability outcome


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.